{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"17"}],"units":"Participants"}],"description":"Evaluate the safety and tolerability of the combination therapy","groups":[{"description":"VELCADE (bortezomib), dexamethasone, and Revlimid (lenalidomide) Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg orally \\[PO\\] on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nLenalidomide: 25 mg PO on Days 1 through 14 of a 3-week cycle for 8 cycles, then stop.","id":"OG000","title":"V-DR"},{"description":"VELCADE (bortezomib), dexamethasone, cyclophosphamide, Revlimid (lenalidomide) Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nCyclophosphamide: 100 - 500 mg/m\\^2 dose PO on Days 1 and 8 of a 3-week cycle for 8 cycles, then stop.\n\nLenalidomide: 15 mg PO on Days 1 through 14 of a 3-week cycle for 8 cycles, then stop.","id":"OG001","title":"VDCR"},{"description":"VELCADE (bortezomib), dexamethasone, cyclophosphamide Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg orally PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nCyclophosphamide: 500 mg/m\\^2 dose PO on Days 1 and 8 of a 3-week cycle for 8 cycles, then stop.","id":"OG002","title":"V-DC"},{"description":"Modified dosing of VELCADE (bortezomib), dexamethasone, cyclophosphamide Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nCyclophosphamide: 500 mg/m\\^2 dose PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.","id":"OG003","title":"VDC-mod"}],"paramType":"NUMBER","populationDescription":"The safety population includes patients received any dose of any study drug.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug through the 30 day post-treatment AE assessment visit","title":"Number of Patients With Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"participants"}